Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

63.45 +0.89 (+1.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomarin Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
Looking Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now. 
Via InvestorPlace
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN). 
Via Chartmill
While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable.
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. 
Via Chartmill
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
Via Benzinga
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Via Benzinga
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. 
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $200 Right Now
A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses. 
Via The Motley Fool
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Earnings Outlook For Biomarin Pharmaceutical
Via Benzinga
15 Analysts Have This to Say About Biomarin Pharmaceutical
Via Benzinga
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month. 
Via InvestorPlace
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments. 
Via InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. 
Via InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
The company's recently FDA-approved gene therapy is struggling to gain traction. 
Via Investor's Business Daily
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a  
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2023
These three lesser-known biotech companies are profitable and growing revenue. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.